300 related articles for article (PubMed ID: 32873483)
1. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
[TBL] [Abstract][Full Text] [Related]
2. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
3. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB
J Transl Med; 2014 Apr; 12():102. PubMed ID: 24745825
[TBL] [Abstract][Full Text] [Related]
5. Comparison of platelet-lymphocyte ratio and CA 19-9 in differentiating benign from malignant head masses in patients with chronic pancreatitis.
Kakkat S; Rajan R; Sindhu RS; Natesh B; Raviram S
Indian J Gastroenterol; 2017 Jul; 36(4):263-267. PubMed ID: 28916969
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
[TBL] [Abstract][Full Text] [Related]
8. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
Xu P; Wang X; Qian J; Li Z; Yao J; Xu A
Medicine (Baltimore); 2021 Feb; 100(6):e24651. PubMed ID: 33578593
[TBL] [Abstract][Full Text] [Related]
9. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
10. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
11. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.
Mellby LD; Nyberg AP; Johansen JS; Wingren C; Nordestgaard BG; Bojesen SE; Mitchell BL; Sheppard BC; Sears RC; Borrebaeck CAK
J Clin Oncol; 2018 Oct; 36(28):2887-2894. PubMed ID: 30106639
[TBL] [Abstract][Full Text] [Related]
12. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
Byeon S; McKay MJ; Molloy MP; Gill AJ; Samra JS; Mittal A; Sahni S
Int J Cancer; 2024 Jul; 155(2):365-371. PubMed ID: 38519999
[TBL] [Abstract][Full Text] [Related]
13. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
14. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.
Chen J; Chen LJ; Xia YL; Zhou HC; Yang RB; Wu W; Lu Y; Hu LW; Zhao Y
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1117-27. PubMed ID: 23546595
[TBL] [Abstract][Full Text] [Related]
15. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the diagnostic and prognostic value of long non-coding RNA SNHG15 in pancreatic ductal adenocarcinoma.
Guo XB; Yin HS; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5892-5898. PubMed ID: 30280769
[TBL] [Abstract][Full Text] [Related]
17. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
18. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
19. Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study.
Jiang D; Yuan X; Ni J; Shen L; Cai M; Xu L
Can J Gastroenterol Hepatol; 2021; 2021():8882129. PubMed ID: 34222137
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma.
Mattila N; Seppänen H; Mustonen H; Przybyla B; Haglund C; Lassila R
Clin Appl Thromb Hemost; 2018 Nov; 24(8):1267-1275. PubMed ID: 29865859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
